$44.85
Insights on Livanova Plc
Revenue is down for the last 2 quarters, 293.9M → 286.1M (in $), with an average decrease of 2.7% per quarter
Netprofit is down for the last 3 quarters, 7.4M → -7.3M (in $), with an average decrease of 396.1% per quarter
In the last 1 year, Stryker Corporation has given 23.1% return, outperforming this stock by 43.2%
In the last 3 years, Boston Scientific Corp. has given 28.3% return, outperforming this stock by 42.5%
0.3%
Downside
Day's Volatility :2.52%
Upside
2.22%
10.23%
Downside
52 Weeks Volatility :32.74%
Upside
25.08%
Period | Livanova Plc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -19.7% | -1.7% | 0.0% |
6 Months | -1.64% | 2.1% | 0.0% |
1 Year | -20.14% | -5.8% | -6.0% |
3 Years | -14.16% | 18.7% | -3.7% |
Market Capitalization | 2.4B |
Book Value | $22.75 |
Dividend Share | 0.0 |
Dividend Yield | 2.34% |
Earnings Per Share (EPS) | 0.05 |
PE Ratio | 882.4 |
PEG Ratio | 5.02 |
Wall Street Target Price | 61.89 |
Profit Margin | 0.26% |
Operating Margin TTM | 1.56% |
Return On Assets TTM | 1.74% |
Return On Equity TTM | 0.24% |
Revenue TTM | 1.1B |
Revenue Per Share TTM | 20.81 |
Quarterly Revenue Growth YOY | 13.3% |
Gross Profit TTM | 696.7M |
EBITDA | 113.0M |
Diluted Eps TTM | 0.05 |
Quarterly Earnings Growth YOY | -0.93 |
EPS Estimate Current Year | 2.7 |
EPS Estimate Next Year | 3.03 |
EPS Estimate Current Quarter | 0.64 |
EPS Estimate Next Quarter | 0.82 |
What analysts predicted
Upside of 37.99%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↓ 16.61% |
Net Income | -25.1M | ↓ 60.03% |
Net Profit Margin | -2.48% | ↑ 2.69% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 9.35% |
Net Income | -189.4M | ↑ 654.58% |
Net Profit Margin | -17.11% | ↓ 14.63% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↓ 2.06% |
Net Income | -155.5M | ↓ 17.9% |
Net Profit Margin | -14.34% | ↑ 2.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 934.2M | ↓ 13.84% |
Net Income | -343.3M | ↑ 120.77% |
Net Profit Margin | -36.75% | ↓ 22.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 10.83% |
Net Income | -135.7M | ↓ 60.47% |
Net Profit Margin | -13.11% | ↑ 23.64% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↓ 1.31% |
Net Income | -86.2M | ↓ 36.48% |
Net Profit Margin | -8.44% | ↑ 4.67% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 254.2M | ↑ 5.84% |
Net Income | 16.4M | ↑ 447.95% |
Net Profit Margin | 6.45% | ↑ 5.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 252.6M | ↓ 0.63% |
Net Income | -107.4M | ↓ 754.88% |
Net Profit Margin | -42.52% | ↓ 48.97% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 274.9M | ↑ 8.83% |
Net Income | 1.7M | ↓ 101.58% |
Net Profit Margin | 0.62% | ↑ 43.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 263.4M | ↓ 4.18% |
Net Income | 7.4M | ↑ 335.29% |
Net Profit Margin | 2.81% | ↑ 2.19% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 293.9M | ↑ 11.58% |
Net Income | 1.2M | ↓ 83.78% |
Net Profit Margin | 0.41% | ↓ 2.4% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 286.1M | ↓ 2.65% |
Net Income | -7.3M | ↓ 708.33% |
Net Profit Margin | -2.55% | ↓ 2.96% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 6.89% |
Total Liabilities | 688.6M | ↑ 8.32% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 1.83% |
Total Liabilities | 1.0B | ↑ 51.9% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↓ 5.41% |
Total Liabilities | 1.0B | ↓ 1.71% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↓ 0.02% |
Total Liabilities | 1.3B | ↑ 25.73% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↓ 8.73% |
Total Liabilities | 906.4M | ↓ 29.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 4.26% |
Total Liabilities | 1.1B | ↑ 19.95% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↓ 3.34% |
Total Liabilities | 1.1B | ↓ 6.3% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 5.28% |
Total Liabilities | 1.1B | ↑ 1.11% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 3.7% |
Total Liabilities | 1.1B | ↑ 2.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 0.0% |
Total Liabilities | 1.1B | ↓ 1.8% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 2.03% |
Total Liabilities | 1.1B | ↑ 3.13% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↓ 0.52% |
Total Liabilities | 1.1B | ↑ 0.26% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 91.3M | ↑ 1.22% |
Investing Cash Flow | -52.9M | ↑ 18.73% |
Financing Cash Flow | 11.3M | ↓ 109.09% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 120.5M | ↑ 31.98% |
Investing Cash Flow | -120.6M | ↑ 128.09% |
Financing Cash Flow | -42.3M | ↓ 474.34% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -91.1M | ↓ 175.6% |
Investing Cash Flow | -41.3M | ↓ 65.75% |
Financing Cash Flow | 146.6M | ↓ 446.57% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -79.4M | ↓ 12.84% |
Investing Cash Flow | -41.8M | ↑ 1.34% |
Financing Cash Flow | 310.8M | ↑ 112.01% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 102.5M | ↓ 229.09% |
Investing Cash Flow | 36.9M | ↓ 188.18% |
Financing Cash Flow | -181.5M | ↓ 158.4% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.2M | ↓ 139.59% |
Investing Cash Flow | -16.1M | ↑ 194.02% |
Financing Cash Flow | -6.3M | ↓ 102.92% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 35.6M | ↓ 448.61% |
Investing Cash Flow | -5.8M | ↓ 63.82% |
Financing Cash Flow | 73.2M | ↓ 1266.64% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 20.8M | ↑ 11.34% |
Investing Cash Flow | -11.5M | - |
Financing Cash Flow | -5.2M | ↑ 208.24% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.0M | ↓ 186.54% |
Investing Cash Flow | -6.7M | ↓ 42.05% |
Financing Cash Flow | 36.0M | ↓ 792.31% |
Sell
Neutral
Buy
Livanova Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Livanova Plc | -10.37% | -1.64% | -20.14% | -14.16% | -56.17% |
![]() Stryker Corporation | 8.92% | 6.38% | 23.08% | 28.28% | 70.41% |
![]() Dexcom, Inc. | 22.72% | -3.4% | -2.13% | 41.0% | 238.3% |
![]() Boston Scientific Corp. | 8.19% | 8.52% | 21.18% | 66.09% | 45.13% |
![]() Abbott Laboratories | 9.77% | 1.43% | -3.37% | -3.87% | 40.42% |
![]() Medtronic Plc | 11.88% | -4.21% | 0.03% | -29.31% | -19.73% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Livanova Plc | 882.4 | 882.4 | 5.02 | 2.7 | 0.0 | 0.02 | 0.02 | 22.75 |
![]() Stryker Corporation | 43.5 | 43.5 | 2.85 | 10.41 | 0.15 | 0.07 | 0.01 | 47.13 |
![]() Dexcom, Inc. | 124.12 | 124.12 | 11.34 | 1.42 | 0.18 | 0.06 | 0.0 | 5.87 |
![]() Boston Scientific Corp. | 67.84 | 67.84 | 2.53 | 2.01 | 0.07 | 0.04 | 0.02 | 12.89 |
![]() Abbott Laboratories | 34.99 | 34.99 | 18.76 | 4.44 | 0.14 | 0.06 | 0.02 | 21.59 |
![]() Medtronic Plc | 25.64 | 25.64 | 3.04 | 5.28 | 0.08 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Livanova Plc | Buy | $2.4B | -56.17% | 882.4 | 0.26% |
![]() Stryker Corporation | Buy | $111.6B | 70.41% | 43.5 | 13.0% |
![]() Dexcom, Inc. | Buy | $43.1B | 238.3% | 124.12 | 11.08% |
![]() Boston Scientific Corp. | Buy | $81.5B | 45.13% | 67.84 | 8.93% |
![]() Abbott Laboratories | Buy | $178.6B | 40.42% | 34.99 | 12.92% |
![]() Medtronic Plc | Buy | $105.1B | -19.73% | 25.64 | 12.84% |
BlackRock Inc
PRIMECAP Management Company
Barrow Hanley Mewhinney & Strauss LLC
Millennium Management LLC
State Street Corporation
Vanguard Group Inc
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
Organization | Livanova Plc |
Employees | 2900 |
CEO | Mr. Damien McDonald |
Industry | Health Technology |